PFIZER, INC. |
Market Closed -
Other stock markets
|
Pre-market 07:02:41 am | |||
| 28.3 USD | -2.01% |
|
28.52 | +0.76% |
| May. 27 | US, European nations consider vaccinating workers exposed to bird flu | RE |
| May. 24 | Novavax awaits FDA decision on whether its next COVID shot can be offered in US | RE |
Financials (USD)
| Sales 2024 * | 60.5B | Sales 2025 * | 62.72B | Capitalization | 160B |
|---|---|---|---|---|---|
| Net income 2024 * | 6.88B | Net income 2025 * | 10.51B | EV / Sales 2024 * | 3.61 x |
| Net Debt 2024 * | 58.11B | Net Debt 2025 * | 51.87B | EV / Sales 2025 * | 3.38 x |
| P/E ratio 2024 * |
21.5
x | P/E ratio 2025 * |
14.5
x | Employees | 88,000 |
| Yield 2024 * |
5.9% | Yield 2025 * |
6.01% | Free-Float | 59.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pfizer, Inc.
More recommendations
More press releases
More news
| 1 day | -0.71% | ||
| 1 week | -0.91% | ||
| Current month | +10.46% | ||
| 1 month | +11.42% | ||
| 3 months | +4.66% | ||
| 6 months | -4.68% | ||
| Current year | -1.70% |
1 week
28.13
29.43
1 month
25.5929.63
Current year
25.2030.28
1 year
25.2040.37
3 years
25.2061.71
5 years
25.2061.71
10 years
25.2061.71
| Managers | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.74% | 254 M€ | +12.51% | - | |
| 9.37% | 17 M€ | +7.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 28.3 | -2.01% | 32,371,217 |
| 24-05-24 | 28.88 | +0.66% | 22,589,127 |
| 24-05-23 | 28.69 | -3.07% | 42,031,325 |
| 24-05-22 | 29.6 | +3.64% | 46,987,481 |
| 24-05-21 | 28.56 | +0.11% | 28,119,948 |
Delayed Quote Nyse, May 28, 2024 at 04:01 pm EDT
More quotes
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.3
USD
Average target price
31.92
USD
Spread / Average Target
+12.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.70% | 160B | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +13.47% | 238B | |
| +7.35% | 204B | |
| -6.42% | 203B | |
| +4.23% | 161B | |
| -1.31% | 120B |
- Stock Market
- Equities
- PFE Stock
